2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
2020
Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations for Management and Next Steps
Jaffe A, Schilsky ML, Deshpande R, Batra R. Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations for Management and Next Steps. Hepatology Communications 2020, 4: 1242-1256. PMID: 32838103, PMCID: PMC7361607, DOI: 10.1002/hep4.1568.Peer-Reviewed Original ResearchEnd-stage liver diseaseLiver transplantLiver transplantationLiver diseaseVirus severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Critical care bedsLife-saving procedureHealth care systemCorona Virus DiseasePosttransplant recipientsCoronavirus 2Transplant programsTumor controlBlood productsCOVID19 infectionCare bedsPatientsStaff contactTransplantCare systemDisease